APRE (Aprea) Company Balance Sheet Assets

Aprea Therapeutics (APRE) is optimizing costs by outsourcing molecule synthesis and initial testing to contract research organizations (CROs). The project's financial foundation relies on grants and research success, as regular sales are absent. Total assets amount to 29.81, as reflected by the shares on this price chart. Aprea Therapeutics (APRE) is developing methods to combat tumors by blocking DNA repair, protecting its developments with patents.

The integration of robotic screening stations and clinical data analysis software systems requires significant capital expenditures, which is reflected in the total assets trend. This indicator, calculated inversely via ROA, aggregates resource value and the company's overall liquidity, allowing investors to assess the financial resilience of Aprea Therapeutics (APRE) to macroeconomic shocks through the balance of equity and liabilities.